DMAAR
Drugs Made In America Acquisition Corp. RightsNASDAQ
Key Statistics
Market Cap
$1.83M
P/E Ratio
—
EPS
—
Beta
—
52W High
$0.24
52W Low
$0.04
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Drugs Made In America Acquisition Corp. Rights
Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company (SPAC) focused on merging with innovative pharmaceutical firms in the United States. With the dual objectives of addressing increasing healthcare demands and mitigating global supply chain disruptions, DMAAR aims to promote cost-effective drug manufacturing solutions that strengthen the domestic pharmaceutical industry. Guided by a seasoned management team, the company is well-positioned to capitalize on growth opportunities in the sector, delivering sustainable value to shareholders while revitalizing American healthcare manufacturing.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -1.46% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.21 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $20.40M |
| Float | $27.31M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
134.59%
HV 20-Day
176.91%
HV 30-Day
172.27%
HV 60-Day
159.59%
HV Rank
94.0%
Volatility is currently contracting
Data last updated: 5/2/2026